Dihexa for Vascular Dementia & Vascular Cognitive Impairment: The 2026 UK Review

Vascular dementia is the second-most-common dementia in the UK — around 150,000 cases, roughly 17% of all dementia — and it is the only common dementia subtype with no NICE-recommended disease-modifying treatment in 2026. In April 2026, UCLA Health researchers uncovered a mechanism by which inflammation in brain blood vessels worsens vascular dementia, and showed that a repurposed psoriasis drug already in clinical trials could promote brain repair in a mouse model. That same month, the UNSW Sydney CHeBA group used Mendelian randomization across 12,000 druggable genes to nominate APOE, TOMM40, ERAP and SAA1-4 as vascular-dementia targets. A University of Manchester team reported that the Kir2.1 channel and the calcium-channel blocker amlodipine protect cerebral microcirculation from hypertensive damage. The World Stroke Organization published its 2026 Vascular Dementia Fact Sheet, and the 2024 Lancet Commission raised the modifiable-risk-factor share of dementia from 40% to 45% with the addition of LDL cholesterol and vision impairment. Where, mechanistically, does Dihexa sit in this rapidly evolving cerebrovascular cognitive picture — and why is the HGF/c-Met biology arguably a cleaner mechanistic fit for vascular dementia than for any other indication on this site? A rigorous 2026 UK evidence review.

Vascular Dementia in the UK 2026: 150,000 People, 17% of All Dementia, Zero NICE Disease-Modifying Options

Vascular dementia is the second-most-common dementia in the UK and the cognitive condition most directly tied to cerebrovascular physiology. The Alzheimer's Society estimates that around 150,000 people in the UK live with vascular dementia, approximately 17% of all dementia cases — roughly 1 in 5. Alzheimer's Research UK places similar estimates in its public-facing material. Vascular dementia is uncommon under age 65 (fewer than 8,000 UK cases), but it is the dementia subtype most directly amenable to upstream risk-factor prevention and most directly tied to the cardiovascular conditions that already dominate UK adult morbidity: hypertension, atrial fibrillation, type 2 diabetes, hyperlipidaemia, obesity and smoking.

The age curve is roughly similar to Alzheimer's disease but with a slightly earlier shoulder — vascular dementia is recognisable from the mid-60s onwards, often emerging in step-wise fashion after a stroke or a series of smaller cerebrovascular events. The 17% prevalence figure understates the true vascular contribution to UK cognitive impairment: mixed dementia — the coexistence of Alzheimer-type pathology with substantial cerebrovascular pathology — is by far the most common neuropathological finding at autopsy in people over 80 with dementia. The "purely vascular" cases captured in the 17% figure are the tip of a much larger vascular contribution iceberg.

The reasons vascular dementia matters disproportionately to UK adult cognitive health are several. First, the underlying risk factors are extremely common and largely modifiable: NHS England prevalence data put hypertension at around 30% of UK adults, type 2 diabetes at around 4.7 million diagnosed (plus several million prediabetes — see the diabetes brain fog review), atrial fibrillation at around 2% (rising sharply with age) and obesity at over 25%. Each of these is independently associated with vascular dementia risk. Second, the licensed-treatment toolkit is essentially empty: NICE NG97 explicitly does not recommend cholinesterase inhibitors or memantine for vascular dementia unless mixed Alzheimer pathology is suspected. Third, the secondary-prevention pharmacotherapy that does exist (antihypertensives, statins, antiplatelets, anticoagulation for AF) is among the highest-evidence-grade interventions in all of medicine — and remains underused in cognitive-impairment populations.

For UK families navigating a vascular dementia diagnosis in 2026, the consequence is a genuine paradox: the disease is highly preventable upstream and almost untreatable downstream. That paradox is exactly the environment in which interest in unlicensed compounds — Dihexa, citicoline, cerebrolysin, methylene blue and others — tends to grow. The editorial position throughout this site remains that the highest-yield first steps for any UK family worried about vascular dementia are a memory-clinic referral via the NICE NG97 dementia diagnosis pathway, a thorough cardiovascular risk-factor review with the GP, and engagement with established UK support organisations — not an unstudied peptide.

The Biology of Vascular Dementia: Big Vessels, Small Vessels, and the Cortical Synapses That Pay the Price

Vascular dementia is a clinically and pathologically heterogeneous group of disorders unified by cerebrovascular insufficiency driving cognitive decline. The clinical subtypes overlap with distinct vascular pathologies, and increasingly with identifiable single-gene causes. Understanding these is the prerequisite for any sensible conversation about an HGF/c-Met-modulating peptide in this disease.

The Main Vascular Dementia Subtypes

Multi-infarct dementia (MID) is the classical large-vessel vascular dementia, caused by accumulated stepwise cognitive decline following multiple cortical or strategic-territory infarcts. The clinical course is typically step-wise, with periods of stability punctuated by acute cognitive worsening after each new stroke. Subcortical ischaemic vascular dementia (SIVD) — also encompassing Binswanger disease in its severe form — is the small-vessel-disease driven subtype, caused by accumulated lacunar infarcts, white matter hyperintensities (leukoaraiosis), microbleeds and subcortical neuronal loss. The clinical course is more typically gradual, with prominent executive dysfunction, gait apraxia, urinary urgency and "frontal" features rather than the temporoparietal cognitive deficits typical of Alzheimer's.

Post-stroke dementia sits at the intersection: dementia emerging within months of an acute stroke. Around 20% of stroke survivors develop dementia within 5 years; up to 30% develop post-stroke cognitive impairment (PSCI) within a year. The dihexa-post-stroke-recovery review on this site (see Dihexa for Stroke Recovery & PSCI) covers PSCI in detail. Strategic infarct dementia occurs when a single stroke in a strategic location (thalamus, hippocampus, angular gyrus, caudate) produces immediate cognitive deficit out of proportion to lesion size. Hypoperfusion-driven cognitive impairment emerges after prolonged systemic hypoperfusion (cardiac arrest, severe hypotension), with selective vulnerability of watershed territories.

Mixed dementia — coexisting Alzheimer-type and vascular pathology — is the most common combination at autopsy. The 17% prevalence figure cited for "pure" vascular dementia in the UK is best understood as a clinical classification rather than a neuropathological one; in practice, most older UK dementia patients have mixed pathology, and treatment decisions (particularly NICE NG97's conditional recommendation of cholinesterase inhibitors and memantine in suspected mixed cases) hinge on this reality.

Cerebral Small Vessel Disease: The Engine of Most Vascular Cognitive Impairment

Cerebral small vessel disease (cSVD) is the umbrella term for pathology of the small arterioles, capillaries and venules that supply deep white matter, basal ganglia, thalamus and cerebellum. cSVD is the engine of subcortical ischaemic vascular dementia and a major contributor to mixed dementia. On MRI, cSVD manifests as white matter hyperintensities (WMH) on FLAIR sequences, lacunar infarcts, cerebral microbleeds (on susceptibility-weighted imaging), perivascular spaces, and brain atrophy disproportionate to age.

The underlying vascular pathology in cSVD includes arteriolosclerosis (the hypertensive vasculopathy), cerebral amyloid angiopathy (overlapping with Alzheimer pathology), inflammatory vasculopathies and, in genetic cases, NOTCH3-driven CADASIL or COL4A1/A2-related disease. The downstream pathophysiology converges on three mechanisms that matter for any drug aimed at this disease: chronic hypoperfusion (deep watershed territories receive marginal blood flow that fails in periods of demand), blood-brain-barrier dysfunction (increasingly recognised as central to cSVD pathology, with subtle BBB leakage detectable on dynamic contrast-enhanced MRI before structural damage is visible), and chronic vascular inflammation with microglial activation in periventricular white matter.

CADASIL and Monogenic Small Vessel Disease

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is the most common single-gene cause of stroke and vascular dementia, caused by mutations in the NOTCH3 gene on chromosome 19. Estimates suggest CADASIL prevalence around 2-5 per 100,000 in the UK, almost certainly an underestimate given diagnostic delay. The clinical sequence is characteristic: migraine with aura starting in young adulthood, recurrent subcortical lacunar strokes in the 40s-50s, cognitive impairment progressing to subcortical vascular dementia in the 50s-60s, and mood disorders throughout. MRI shows characteristic anterior-temporal-pole white matter hyperintensities that are highly specific.

A 2025 Science Advances paper using a 3D vessel-on-chip model with iPSC-derived vascular smooth muscle cells from CADASIL patients showed that phosphodiesterase-5 inhibition rescued NOTCH3-driven vascular smooth-muscle dysfunction. Disease severity staging in CADASIL is now formalised (JAMA Neurology 2024 NOTCH3-associated small vessel disease severity staging system) and 2-year clinical and radiologic progression metrics are sensitive enough to support trial endpoints (Neurology 2024). Rarer monogenic small-vessel diseases include CARASIL (HTRA1), COL4A1/A2 vasculopathy, and the Fabry disease small-vessel phenotype. For UK CADASIL families, the Cambridge CADASIL clinic and the UCL Rare Dementia Support service are the primary tertiary resources.

The Cortical Synaptic Endpoint

Whatever the upstream vascular pathology, the downstream cellular endpoint of cognitive decline in vascular dementia is the same as in Alzheimer's, frontotemporal dementia and most other neurodegenerative dementias: loss of dendritic spines, reduction in cortical synaptic density, and degradation of long-range cortical connectivity. The vascular cause produces the synaptic endpoint via a combination of direct ischaemic neuronal injury, chronic hypoperfusion-driven metabolic compromise, BBB-leakage-driven neuroinflammation and microglia-mediated synaptic pruning.

This is the substrate that a synaptogenic intervention — any synaptogenic intervention — would aim to repair. The argument applies to chronic-phase vascular dementia in much the same way it applies to the synaptic loss described in the MCI and brain aging review and the post-stroke phase covered in the stroke recovery review. The HGF/c-Met biology, importantly, is not just synaptogenic — it is also angiogenic and BBB-protective, which is what makes vascular cognitive impairment a closer mechanistic fit than essentially any other indication on this site.

The HGF/c-Met System and Vascular Dementia: Why the Mechanistic Fit Is Unusually Clean

Across most indications on this site, the mechanistic argument for an HGF/c-Met-modulating peptide rests primarily on synaptogenesis and microglial polarisation. For vascular dementia, the case is broader and arguably more coherent than for any other indication. Hepatocyte growth factor is fundamentally a vascular-system growth factor, and the documented cerebrovascular roles of HGF/c-Met overlap with the disease physiology of vascular cognitive impairment at multiple distinct levels.

HGF and Cerebral Angiogenesis

HGF is one of the most potent endogenous regulators of cerebral angiogenesis. The 2015 review of HGF's therapeutic potential against cerebral ischaemia documents that exogenous HGF administration in rat middle cerebral artery occlusion (MCAO) models promotes strong neurogenesis, angiogenesis, synaptogenesis and antifibrotic effects in the affected hemisphere — with a key advantage over VEGF-based angiogenic therapies that is directly relevant to vascular dementia: HGF promotes microvascular growth without disrupting the blood-brain barrier, without increasing cerebral oedema, without driving vascular inflammation, and with anti-thrombotic properties.

For chronic hypoperfusion-driven vascular dementia, this combination of properties is unusually attractive. The therapeutic problem in subcortical ischaemic vascular dementia is that deep watershed territories live on the edge of their oxygen supply; any intervention that promotes microvascular regeneration in these territories has direct mechanistic relevance to the disease physiology. The mechanism is well documented in the basic-science literature; the translational gap to clinical vascular dementia trials, however, is unbridged for Dihexa specifically.

HGF and the Blood-Brain Barrier

The recognition that blood-brain-barrier dysfunction is central to cerebral small vessel disease pathology (and not just a downstream consequence) has been one of the most important conceptual shifts in vascular dementia research over the last decade. Subtle BBB leakage, detectable on dynamic contrast-enhanced MRI, is now recognised as an early marker of cSVD and a likely contributor to the chronic perivascular inflammation that drives white-matter damage and microglial activation.

HGF, uniquely among angiogenic growth factors, seals rather than disrupts the blood-brain barrier in cerebral ischaemia models. The mechanism is supported by multiple lines of evidence: HGF-induced endothelial tight-junction protein expression, reduction of post-ischaemic BBB permeability, and direct anti-oedemic effects. For a vascular cognitive impairment indication where BBB leakage is increasingly central to the pathophysiology, this is a mechanistically relevant property that distinguishes HGF/c-Met-targeted therapeutics from VEGF-class angiogenic alternatives.

HGF/c-Met on Microglia in Chronic Cerebral Hypoperfusion

c-Met is expressed on microglia and HGF signalling has been shown in multiple CNS contexts to shift microglial polarisation away from pro-inflammatory phenotypes and towards reparative ones. The recent UCLA Health 2026 vascular dementia work identified inflammation in brain blood vessels as a central driver of disease progression, with successful intervention by a repurposed psoriasis drug acting on vascular-cell-brain-cell crosstalk. The mechanism specifically targets the chronic vascular-inflammatory loop that converts marginal hypoperfusion into accumulating white-matter damage.

HGF/c-Met biology overlaps with this picture conceptually. The endogenous HGF response to cerebral ischaemia includes a microglial component that supports debris clearance, dampens excessive inflammatory signalling and promotes tissue remodelling. A positive modulator of this axis would, on paper, address the same vascular-inflammation-microglial-pruning pathology that the UCLA work is targeting via a different mechanism. None of this constitutes evidence; the mechanistic overlap is at most a hypothesis-generating observation.

HGF/c-Met and Cortical Synaptogenesis

The Wright laboratory's original Dihexa work was framed around angiotensin-IV-derived peptides for Alzheimer's and Parkinson's disease (Wright & Harding, Neuroscience 2015); Benoist and colleagues showed that the procognitive and synaptogenic effects of these peptides require HGF/c-Met activation. The cellular substrate is loss of dendritic spines and reduced cortical synaptogenesis; the proposed restorative pathway is HGF-driven PI-3K/AKT signalling supporting spine formation and synaptic maintenance.

For vascular dementia, this means that an HGF/c-Met-positive modulator addresses the disease physiology at four distinct levels simultaneously: angiogenesis (repairing the microvascular insufficiency that drives chronic hypoperfusion), BBB sealing (addressing the central role of BBB leakage in cSVD), microglial repolarisation (dampening the chronic vascular inflammation that converts marginal hypoperfusion into white-matter damage), and synaptogenesis (rebuilding the downstream cortical synaptic substrate of cognitive decline). The mechanistic case for vascular dementia is arguably cleaner than for any other indication on this site. The evidence case remains, as elsewhere, empty.

The BDNF Axis in Vascular Cognitive Impairment

BDNF — the dominant neurotrophin supporting adult human cortical synaptic maintenance — is reduced in chronic cerebral hypoperfusion models and in subcortical ischaemic vascular dementia. CSF BDNF is lower in symptomatic VCI patients than age-matched controls; cortical TrkB receptor signalling is disrupted by chronic ischaemia. The biology overlaps directly with the Dihexa vs BDNF article: synaptogenic interventions that engage the BDNF-supported substrate of cortical plasticity are mechanistically aligned with the deficit vascular dementia produces. The frequently-cited "10 million times more potent than BDNF" claim does not directly close the BDNF deficit in VaD, but the synaptogenic logic at least overlaps with the documented neurotrophin and synaptic deficits.

Putting these strands together: the mechanistic case for an HGF/c-Met-targeted peptide in vascular dementia is unusually broad. Angiogenesis, BBB sealing, microglial repolarisation and synaptogenesis all align with VCI disease physiology. What the case conspicuously lacks — consistent with every other Dihexa indication review — is any experimental data in vascular dementia. No in vitro work in human cerebral endothelial-cell models exposed to chronic hypoxia; no in vivo work in bilateral common carotid artery occlusion (BCCAO) rodent models of chronic cerebral hypoperfusion; no work in the spontaneously hypertensive stroke-prone rat (SHRSP) model of small vessel disease; and zero human trial data. The mechanism deserves a real experiment.

The April 2026 UCLA Breakthrough: Inflammation, Blood Vessels and a Psoriasis Drug Repurposed for Vascular Dementia

The single most important basic-science vascular dementia event of early 2026 happened at UCLA Health. The work re-frames vascular dementia not as a passive consequence of cerebrovascular insufficiency but as an active inflammatory disease of cerebral blood vessels, with implications that reach across the field.

The Mechanism

The UCLA Health team identified a specific inflammatory pathway in cerebral blood-vessel endothelial cells that, when activated chronically, drives the brain damage of vascular dementia. The pathway involves crosstalk between vascular endothelial cells and adjacent brain cells (astrocytes, microglia, neurons), with the inflammation in the vessel wall propagating to surrounding brain tissue and driving the chronic neuroinflammatory loop that converts marginal blood flow into accumulating cognitive damage. The work was framed around the recognition that vascular dementia is not simply "Alzheimer's that happens to have small infarcts" but a distinct disease driven by chronic vascular inflammation.

The implication for therapeutics is direct: targeting the vascular-cell-brain-cell inflammatory crosstalk — rather than just the strokes or the dementia symptoms — could address vascular dementia at the root.

The Repurposed Drug

The therapeutic candidate used in the UCLA mouse model is a drug already in clinical trials for psoriasis (an inflammatory skin condition driven by similar T-cell-mediated inflammatory pathways). The choice was deliberate: an existing inflammation-targeting drug with established safety in humans, available for rapid repurposing if mechanistic proof-of-concept held. In the mouse model, the drug promoted both brain repair and functional recovery from vascular dementia.

The single most clinically resonant finding was that delayed intervention still worked. Vascular dementia is consistently diagnosed late — often after substantial white-matter damage has accumulated — and the field has long worried that disease-modifying intervention is only possible early. The UCLA finding that the repurposed drug worked even with delayed administration is the strongest single signal in 2026 that brain repair (rather than just prevention) is mechanistically possible in vascular dementia.

Implications for the Field and for Dihexa Mechanistic Discussion

The UCLA work does not validate HGF/c-Met-targeted approaches. It does, however, validate the more general principle that vascular dementia has a distinct, modifiable inflammatory mechanism distinct from the strokes themselves. That conceptual shift is the framework into which other mechanistic candidates — angiogenic, BBB-protective, microglia-modulating, synaptogenic — can be evaluated. The HGF/c-Met biology touches several of these levels simultaneously.

For UK patients reading this, the practical 2026 implications are limited but real. The UCLA work is preclinical, in a mouse model, and a psoriasis-drug repurposing for vascular dementia would require dedicated Phase 2/3 trials before any meaningful clinical use. The Inside Precision Medicine 2026 summary emphasises the multi-year timeline ahead. But the news is mechanistically genuinely important and reasonably actionable: it suggests that vascular dementia is a treatable disease in principle, that brain repair is mechanistically possible even after substantial damage, and that the next 5-10 years of VaD pharmacotherapy is likely to look meaningfully different from the empty cupboard of 2026.

UNSW Sydney CHeBA April 2026: Mendelian Randomization Across 12,000 Genes Nominates APOE, TOMM40, ERAP and SAA1-4

Within the same month as the UCLA work, the UNSW Sydney Centre for Healthy Brain Aging (CHeBA) published a complementary piece of work that approached the same problem from genetics rather than inflammation biology. The methodology — Mendelian randomization across approximately 12,000 "druggable" genes — is one of the most rigorous causal-inference frameworks available in genetic epidemiology.

The Mendelian Randomization Approach

Mendelian randomization exploits the random allocation of genetic variants at conception to infer causal direction between a putative exposure (here, expression of a druggable gene) and an outcome (vascular dementia diagnosis). Unlike conventional epidemiology — where reverse causation, confounding and selection bias make causal inference difficult — Mendelian randomization is robust to most of these biases because genetic variants are fixed at birth and largely random with respect to typical confounders. The trade-off is statistical power, which is addressed in the UNSW CHeBA work by using large GWAS summary statistics covering the entire druggable genome.

The Four Targets: APOE, TOMM40, ERAP, SAA1-4

The headline finding was that four genes emerged as candidate causal targets for vascular dementia: APOE (apolipoprotein E, the dominant Alzheimer's risk gene, also strongly associated with vascular dementia), TOMM40 (translocase of outer mitochondrial membrane 40, immediately adjacent to APOE on chromosome 19, with its own independent dementia signals), ERAP (endoplasmic reticulum aminopeptidase, involved in MHC class I antigen processing and inflammatory pathways) and SAA1-4 (serum amyloid A 1-4, acute-phase reactants with inflammatory and amyloidogenic properties).

Two of these — APOE and TOMM40 — were independently linked to neuroimaging markers of cerebral small vessel disease (white matter hyperintensities and lacunar infarct burden). The biological theme that emerges is striking: of the four causal targets, three (APOE, ERAP, SAA1-4) have established roles in inflammation and amyloid biology, and the fourth (TOMM40) sits in mitochondrial function. This converges on the broader 2026 view of vascular dementia as a disease of chronic vascular inflammation plus mitochondrial vulnerability in a context of marginal cerebral blood flow.

Implications for HGF/c-Met Discussion

The UNSW findings do not validate Dihexa or any HGF/c-Met-targeted approach. They do, however, suggest that the next wave of vascular dementia therapeutics is likely to combine inflammation modulation, vascular biology and synaptic protection — not focus on a single pathway. A growth-factor system like HGF/c-Met that touches multiple levels of vascular and synaptic biology is, in this conceptual frame, the kind of target that deserves serious experimental evaluation. The mechanistic argument continues to be more interesting than the evidence base allows.

University of Manchester Kir2.1 / Amlodipine: A Mechanistic Rationale for an Existing NHS Antihypertensive

Sitting alongside the UCLA inflammation work and the UNSW genetics work, a third 2026 paper from the University of Manchester Faculty of Biology, Medicine and Health identified a different but complementary mechanism: the role of the inward-rectifier potassium channel Kir2.1 in matching cerebral blood flow to local neuronal activity, and the rescue of Kir2.1 function by the licensed calcium-channel-blocker amlodipine.

The Kir2.1 Mechanism

Kir2.1 is expressed on cerebral endothelial cells and is part of the molecular machinery that allows local neuronal activity to drive local microvascular dilatation — the process known as functional hyperaemia or neurovascular coupling. In chronic hypertension, Kir2.1 function is progressively impaired, neurovascular coupling fails, and the matching of cerebral blood flow to neuronal demand breaks down. The Manchester team showed in a mouse model that amlodipine restored Kir2.1 function and improved cerebral microcirculation, with downstream cognitive benefits.

Implications for UK Practice

Amlodipine is among the most-prescribed antihypertensives on the NHS — it is licensed, generic, low-cost and well-tolerated. The Manchester work provides a specific cerebral-microcirculation mechanism by which the cardiovascular benefit of amlodipine in hypertensive patients may extend to cognitive benefit. The result is consistent with the broader SPRINT-MIND-era evidence that intensive blood-pressure lowering reduces incident MCI, and it strengthens the case for amlodipine-class antihypertensive choice in patients at vascular dementia risk — though the choice should always be individualised by the prescribing clinician based on cardiovascular factors.

For the Dihexa discussion, the Manchester work matters less for direct mechanism-overlap and more for what it implies about combination biology: vascular dementia is a disease where multiple-pathway intervention (BP control + lipid control + glycaemia + inflammation + endothelial function + synaptic plasticity) is likely to outperform single-pathway intervention. Any peptide intervention would be working alongside, not instead of, the standard vascular-prevention pharmacotherapy — and the editorial position remains that NICE-aligned vascular pharmacotherapy must not be discontinued for any unlicensed peptide.

The World Stroke Organization 2026 Vascular Dementia Fact Sheet

In 2026 the World Stroke Organization (WSO) published its updated Vascular Dementia Fact Sheet, accompanied by a podcast series featuring Profs Vladimir Hachinski, Geert-Jan Biessels and other senior figures in the field. The fact sheet (also published in the International Journal of Stroke and indexed on PubMed) is the most authoritative current overview of vascular dementia from a stroke-medicine perspective and is freely available.

Definitions and Diagnostic Frame

The WSO 2026 Fact Sheet uses the term vascular cognitive impairment (VCI) as the umbrella, with vascular dementia (VaD) referring specifically to cases reaching the dementia threshold. This terminology shift — from "vascular dementia" as the headline term to "VCI" as a broader umbrella encompassing mild cognitive impairment of vascular origin — reflects the 2025-2026 consensus that earlier-stage intervention is the most realistic therapeutic target.

Prevention

The fact sheet emphasises that vascular dementia is the dementia subtype most directly preventable through vascular risk-factor control. The prevention frame aligns with the 2024 Lancet Commission's 14 modifiable risk factors and with the SPRINT-MIND-era evidence on intensive blood-pressure control. The single highest-yield intervention for vascular dementia prevention in 2026 remains aggressive control of hypertension, with a target systolic BP under 130 mmHg in tolerant patients.

Management

The WSO fact sheet's management frame includes acute-stroke management, secondary prevention (antiplatelet or anticoagulation as appropriate, statin therapy, BP and glycaemic control), multidisciplinary rehabilitation, cognitive rehabilitation and supportive care. Pharmacotherapy specifically for the cognitive component remains limited: the fact sheet acknowledges the modest evidence for cholinesterase inhibitors and memantine in mixed Alzheimer-vascular dementia (consistent with NICE NG97) and notes the ongoing trial pipeline (MarkVCID consortium, NAC, CY6463) without recommending any specific disease-modifying therapy.

For UK readers, the WSO 2026 Fact Sheet is the single most useful free-to-access lay-clinical reference on vascular dementia available in 2026, and it should be the first stop for any UK family seeking authoritative independent information on the disease.

The 2026 Vascular Dementia Pipeline: MarkVCID, CY6463, NAC, NOTCH3 PDE-5 Approaches

Compared with Alzheimer's disease — where the 2023-2025 lecanemab and donanemab approvals (rejected by NICE for NHS use in 2026, see the MCI & brain aging review) have dominated the conversation — the vascular dementia pipeline is sparser. Several programmes are nevertheless worth tracking.

The MarkVCID Consortium

The MarkVCID consortium (Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia), funded by the US NIH, is the largest current effort to validate vascular dementia biomarkers in 1800 participants. The consortium's outputs will define the biomarker landscape for the next generation of VCI trials — analogous to the role the ADNI consortium played in establishing the Alzheimer's biomarker frame in the 2010s. The Phase 2 MarkVCID effort, MarkVCID2, is the operational evolution of the consortium and is expected to deliver fully-validated biomarker panels supporting Phase 3 vascular dementia drug trials by 2027-2028.

CY6463 (Soluble Guanylate Cyclase Stimulator)

CY6463 is a soluble guanylate cyclase (sGC) stimulator developed by Cyclerion (now under Tisento Therapeutics) with the therapeutic logic that nitric-oxide-sGC-cGMP signalling is impaired in vascular cognitive impairment, particularly in CADASIL and small vessel disease. Phase 2 trials in Alzheimer's with vascular pathology and in CADASIL have explored CY6463's safety and pharmacodynamic effects. The recent 3D vessel-on-chip CADASIL work (Science Advances 2025) showed PDE-5 inhibition rescuing NOTCH3-driven vascular smooth-muscle-cell dysfunction — a related mechanism that strengthens the broader nitric-oxide / cGMP frame in cSVD.

N-Acetylcysteine (NAC) Phase 2

A Canadian Phase 2 RCT randomised vascular cognitive impairment patients to NAC or placebo for 24 weeks. NAC is a long-marketed mucolytic and antioxidant with established safety. The trial was designed to test whether reducing oxidative stress could slow VCI progression. Results have been variable across analyses; NAC has not entered NICE-recommended UK practice for VCI but remains a low-risk research-grade intervention in some international protocols.

Other Programmes

Multiple smaller programmes deserve mention. Cilostazol (an antiplatelet PDE-3 inhibitor used in peripheral arterial disease) has shown signals in subcortical ischaemic vascular dementia in several Asian trials and is under continuing investigation. Memantine and donepezil have small-trial evidence in mixed dementia but are not NICE-recommended for pure vascular dementia. Cerebrolysin (porcine-brain-derived neuropeptide mixture) has a substantial Eastern European trial base in VaD with mixed results and methodological heterogeneity (see the Dihexa vs nootropics comparison). Phosphodiesterase-5 inhibitors are being repositioned for CADASIL based on the 2025 Science Advances vessel-on-chip work. SGLT2 inhibitors (empagliflozin, dapagliflozin) have emerging post-hoc analyses in mixed cardiovascular cohorts suggesting cognitive benefit; ongoing trials will clarify. The 2022 review of clinical trials for VCI/VaD drugs is the most comprehensive single roundup; the 2026 Neuropsychopharmacology review updates the picture.

For the Dihexa-specific reader, the consequence is that the vascular dementia pipeline is meaningfully active but mostly in early-phase development. No flagship Phase 3 failure has occurred in pure VaD as recently as in FTD (the latozinemab INFRONT-3 failure covered in the FTD review) or Alzheimer's (the EVOKE / EVOKE+ semaglutide failure covered in the diabetes brain fog review). The conservative reading is that the 2026-2028 vascular dementia pipeline will likely produce mixed results and incremental progress, not transformative breakthroughs — consistent with the broader pattern in neurodegeneration. The aggressive reading is that the unusually clean mechanistic biology of vascular dementia (angiogenesis + BBB sealing + inflammation modulation + synaptic protection) leaves more therapeutic room than the slower, more amyloid-locked Alzheimer's field.

Vascular Dementia Care in the UK in 2026: The Diagnostic Pathway, the Risk-Factor Reality, the Treatment Gap

The honest comparison most families want is between Dihexa and the interventions a UK vascular dementia pathway actually uses. As elsewhere on this site, the comparison is mechanism-level different — these interventions operate on completely different parts of the disease trajectory — but worth working through.

The UK Diagnostic Pathway

Suspected vascular dementia is typically referred from primary care into a memory clinic or cognitive neurology service via the standard NICE NG97 dementia diagnosis pathway. Initial assessment includes neuropsychological testing (typically the Addenbrooke's Cognitive Examination ACE-III or the Montreal Cognitive Assessment MoCA, with the MoCA tending to be more sensitive to the executive-dysfunction profile of subcortical ischaemic VaD), structural neuroimaging (MRI is preferred where available; NICE specifies that vascular dementia should not be diagnosed on vascular-lesion burden alone), and where available volumetric MRI assessment.

The Hachinski Ischemic Score remains a useful bedside tool for distinguishing vascular dementia from Alzheimer's: stepwise progression, fluctuating course, history of stroke or TIA, hypertension, focal neurological signs and focal neurological symptoms all support a vascular contribution. The score is not perfect (mixed pathology is common and the score does not handle it well) but it remains widely used.

The cardiovascular workup that should accompany vascular dementia diagnosis includes 12-lead ECG (looking for atrial fibrillation or LV hypertrophy), echocardiography in selected cases, carotid Doppler ultrasound where territorial stroke pattern is present, blood pressure measurement (ideally with 24-hour ambulatory monitoring), fasting glucose and HbA1c, lipid profile and routine bloods. The Hachinski-Mesulam emphasis on a thorough cardiovascular workup remains the standard of care.

Secondary Prevention: The Highest-Evidence Intervention

For vascular dementia and vascular cognitive impairment, the area of the treatment toolkit with the strongest evidence is, by some distance, secondary prevention of vascular risk factors. This is also the area where most patients have the most to gain:

• Blood pressure control — target systolic BP under 130 mmHg in tolerant patients (the SPRINT-MIND benchmark). Amlodipine, ramipril, losartan and indapamide are the typical NHS first-line agents. The Manchester Kir2.1 / amlodipine paper provides cerebrovascular-specific mechanism for amlodipine.
• Lipid control — atorvastatin or rosuvastatin to target LDL-C; the 2024 Lancet Commission added LDL cholesterol as a modifiable dementia risk factor.
• Antiplatelet or anticoagulation therapy — aspirin or clopidogrel for symptomatic carotid or cerebral large-vessel disease; DOACs (apixaban, edoxaban, rivaroxaban, dabigatran) or warfarin for atrial fibrillation. Anticoagulation for AF is one of the highest-yield interventions in all of medicine and is underused in older UK patients.
• Glycaemic control in type 2 diabetes — metformin, SGLT2 inhibitors, GLP-1 receptor agonists, with cognitive-protection signals increasingly recognised. See the diabetes brain fog review for the SGLT2 and GLP-1 cognitive evidence base.
• Smoking cessation, weight management, physical activity, moderate alcohol, hearing aid use, vision correction — the Lancet Commission's 14 modifiable risk factors.

Pharmacotherapy for the Cognitive Component

The UK pharmacotherapy options specifically for the cognitive component of vascular dementia are limited. NICE NG97 is explicit: cholinesterase inhibitors and memantine should not be offered for vascular dementia unless there is suspected comorbid Alzheimer's disease, Parkinson's-disease dementia or dementia with Lewy bodies. The licensed anti-amyloid therapies (lecanemab, donanemab) do not target vascular pathology. SSRIs are sometimes used for the depression that frequently complicates VaD; antipsychotics are used cautiously and only when necessary for severe behavioural symptoms.

The 2026 reality is that there is no NICE-recommended disease-modifying treatment for pure vascular dementia. This is the area of cognitive neurology where the gap between unmet need and licensed pharmacotherapy is arguably the most painful. Mixed dementia, where Alzheimer pathology is suspected to coexist, is a partial exception — cholinesterase inhibitors are reasonable in this setting under NICE.

Multidisciplinary Care and UK Support Organisations

Where pharmacotherapy is empty, multidisciplinary care has substantial value. Stroke rehabilitation (where applicable), cognitive rehabilitation (memory aids, environmental adaptation, executive-function strategies), occupational therapy, specialist dementia nursing (Admiral Nurses via Dementia UK or memory-clinic-based clinical nurse specialists) and social work input for capacity assessment, lasting power of attorney, advance care planning and benefits navigation are the cornerstones of UK practice.

For UK families affected by vascular dementia, the three most important support organisations in 2026 are:

• Alzheimer's Society (vascular dementia information hub) — the UK's largest dementia charity, providing the Dementia Connect support line (0333 150 3456), local services and online community.
• Alzheimer's Research UK (vascular dementia information) — the UK's leading dementia research charity, funding substantial vascular dementia research including the UK Dementia Research Institute's vascular focus.
• Stroke Association (stroke.org.uk, helpline 0303 3033 100) — directly relevant given the overlap between stroke recovery and vascular dementia care.
• Dementia UK (dementiauk.org) — Admiral Nurse Dementia Helpline on 0800 888 6678, the only specialist dementia nurse service in the UK.

The contrast with the Dihexa proposition is sharp: established, free-at-the-point-of-use, multidisciplinary support exists in the UK and is consistently underused. Asking your GP for a memory clinic referral, accessing the Admiral Nurse helpline and engaging with the Alzheimer's Society Dementia Connect line are evidence-grade interventions in a way that an unlicensed peptide is not.

Mixed Dementia: Where Vascular and Alzheimer Pathology Coexist

One of the most clinically important — and most consistently underestimated — aspects of UK dementia care is the prevalence of mixed dementia, the coexistence of substantial Alzheimer-type pathology with substantial cerebrovascular pathology in the same patient. At neuropathology, mixed disease is by some distance the most common finding in dementia cases over 80; "pure" Alzheimer's and "pure" vascular dementia are minority pathologies in this older age band.

Clinically, mixed dementia presents as a combination of Alzheimer-type features (gradual progressive memory loss, temporoparietal atrophy on MRI, possibly positive amyloid biomarkers) and vascular features (stepwise progression at points, focal neurological signs, vascular lesions on MRI). The distinction matters for NICE-aligned treatment: NICE NG97 allows cholinesterase inhibitors and memantine in suspected mixed dementia, even when vascular pathology is prominent.

For the Dihexa discussion, mixed dementia is mechanistically interesting because both upstream contributions — Alzheimer amyloid pathology and cerebrovascular insufficiency — converge on the same downstream cortical synaptic substrate. An HGF/c-Met-positive modulator addressing synaptogenesis would, in principle, address the downstream substrate independent of upstream cause. The same caveat applies as everywhere on this site: zero human Dihexa data in mixed dementia, in pure vascular dementia, or in any vascular cognitive impairment population. The mechanistic case overlaps with the broader Alzheimer's discussion covered in our Alzheimer's research review.

For UK families, the practical implication of mixed dementia is that an Alzheimer's-style cholinesterase inhibitor trial under NICE NG97 is often reasonable even when vascular features are prominent — with the prescribing decision made by the memory clinic specialist. This is the closest thing to a NICE-recommended pharmacological option in vascular-dementia-spectrum disease, and it deserves to be considered before any unlicensed alternative.

The 2024 Lancet Commission and the 45% Preventable Vascular Dementia Story

If vascular dementia in 2026 has any silver lining, it is the prevention story. The 2024 Lancet Commission on dementia prevention reported that 45% of global dementia cases could be delayed or prevented by addressing 14 modifiable risk factors — up from 12 risk factors and 40% in the 2020 update. The new additions are elevated LDL cholesterol (mid-life) and uncorrected vision impairment (late life). The Alzheimer's Disease International summary is the cleanest lay version.

Of the 14 modifiable risk factors, the majority are directly vascular: hypertension, type 2 diabetes, obesity, physical inactivity, smoking, excessive alcohol, air pollution, traumatic brain injury, and now elevated LDL cholesterol. Hearing loss and vision impairment have less direct vascular mechanism but plausibly act through cognitive-reserve and engagement pathways. Less education in early life, social isolation in late life and depression complete the list. The vascular dementia subtype is the area where modifiable risk-factor control has by far the strongest evidence base.

The SPRINT-MIND trial — the cognitive sub-study of the landmark SPRINT trial of intensive vs standard blood pressure control — remains the single most influential trial in vascular dementia prevention. Intensive BP control (target systolic under 120 mmHg) reduced incident mild cognitive impairment by approximately 19% relative to standard control. The Manchester Kir2.1 / amlodipine paper provides cerebrovascular-specific mechanism for one of the standard antihypertensive classes underpinning this benefit.

For UK patients in their 40s, 50s and 60s — the window in which most of the Lancet Commission's risk-factor benefits are realised — the prevention message is unambiguous and far higher-yield than any peptide intervention. Aggressive control of blood pressure, lipids, glycaemia and weight, smoking cessation, regular physical activity, moderate alcohol and engagement with NHS hearing and vision services together address the upstream drivers of vascular dementia in a way that any downstream brain-repair intervention cannot. The single highest-yield "anti-dementia" action a UK adult can take in 2026 is not buying an unlicensed peptide; it is going to their GP for a comprehensive cardiovascular risk-factor review.

2026 Vascular Dementia News: What Is Actually Happening This Year

The following 2025-2026 events frame the contemporary UK and global vascular dementia landscape and are referenced where relevant in this article:

• April 2026 — UCLA Health vascular dementia brain repair mechanism: UCLA researchers identified inflammation-driven vascular-cell-brain-cell crosstalk as a key VaD progression mechanism and showed that a repurposed psoriasis drug, already in human trials, promoted brain repair and functional recovery in a VaD mouse model. Delayed intervention still worked.
• April 2026 — UNSW Sydney CHeBA Mendelian randomization study: The UNSW Centre for Healthy Brain Aging screened ~12,000 druggable genes via Mendelian randomization and nominated APOE, TOMM40, ERAP and SAA1-4 as candidate causal targets for vascular dementia, with APOE and TOMM40 also linked to neuroimaging markers of small vessel disease.
• 2026 — University of Manchester Kir2.1 / amlodipine paper: Manchester researchers identified Kir2.1 as a critical channel for cerebral neurovascular coupling and showed that amlodipine restored Kir2.1 function and cerebral microcirculation in hypertensive mice — a direct cerebrovascular-cognitive rationale for an existing NHS antihypertensive class.
• 2026 — World Stroke Organization Vascular Dementia Fact Sheet: The WSO published its updated 2026 Vascular Dementia Fact Sheet with an accompanying podcast series featuring Hachinski, Biessels and other senior figures; the most authoritative current overview of vascular dementia.
• 2026 — Neuropsychopharmacology vascular cognitive impairment review: The Nature Neuropsychopharmacology 2026 VCI review synthesised the prevention, treatment, mechanism and management landscape.
• 2025 — Science Advances CADASIL phosphodiesterase-5 rescue: The 2025 Science Advances paper used a 3D vessel-on-chip with iPSC-derived CADASIL vascular smooth-muscle cells and showed PDE-5 inhibition rescued NOTCH3-driven dysfunction — the most significant CADASIL-specific therapeutic lead in 2025-2026.
• 2024 — Lancet Commission on dementia prevention update: The 2024 Lancet Commission raised the modifiable-risk-factor share of dementia from 40% to 45% by adding LDL cholesterol (mid-life) and uncorrected vision (late life) to the list of 12 factors recognised in the 2020 update.
• 2024 — JAMA Neurology NOTCH3 severity staging: JAMA Neurology published a formal disease severity staging system for NOTCH3-associated small vessel disease, supporting future CADASIL trial design.
• 2024 — Neurology 2-year NOTCH3 progression metrics: Neurology reported that NOTCH3 variant risk category predicts 2-year clinical and radiologic small-vessel-disease progression, supporting trial-sensitive endpoints.
• Continuing — MarkVCID consortium: The US NIH-funded MarkVCID and MarkVCID2 consortia are building the biomarker infrastructure for vascular dementia drug development across 1800+ participants, on track to support Phase 3 VCI trials in 2027-2028.
• Continuing — UK Dementia Research Institute vascular focus: The UK DRI hosts several major vascular dementia research programmes; the broader UK academic landscape is summarised at ukdri.ac.uk.

The 2026 trajectory for vascular dementia is, on balance, more encouraging than for some other neurodegenerative conditions. The mechanistic understanding has advanced substantially in 2025-2026 (UCLA, UNSW CHeBA, Manchester, Science Advances CADASIL); the prevention frame is the strongest of any dementia subtype; the existing secondary-prevention pharmacotherapy is among the highest-evidence-grade in all of medicine. The disease-modifying pharmacotherapy cupboard for the cognitive component, however, remains essentially bare under NICE NG97 — which is the gap into which interest in unlicensed compounds flows. Understandable patient and family demand in an environment where licensed cognition-specific options are zero.

Practical Realities: If a Family Affected by Vascular Dementia Is Considering Dihexa

This site exists because people will research Dihexa whether or not we cover it. The honest editorial position for families considering Dihexa in the context of a vascular dementia or vascular cognitive impairment diagnosis is that the standard NHS pathway — specialist memory-clinic diagnosis, cardiovascular risk-factor optimisation, multidisciplinary care, support-organisation engagement and clinical-trial participation where appropriate — should be in place first, full stop. For families nevertheless determined to explore, the harm-reduction frame looks like the following.

Vascular-Dementia-Specific Cautions

A reasonable list of absolute and relative reasons not to self-experiment in the vascular dementia context, drawing on the broader side effects review:

• Anyone with recent (within 6 months) stroke, TIA or acute coronary syndrome — the acute-phase cerebrovascular environment is the most volatile and least understood for any unstudied peptide intervention.
• Anyone on dual antiplatelet therapy (DAPT after recent stroke or coronary stenting) or therapeutic anticoagulation (warfarin, DOAC) for atrial fibrillation — uncharacterised interactions with antiplatelet and anticoagulant pharmacology, with cerebral microbleed risk already elevated by cSVD.
• Anyone with significant cardiovascular comorbidity, particularly heart failure, severe valvular disease or recurrent atrial fibrillation — the brain renin-angiotensin axis with which the angiotensin-IV-derived Dihexa class interacts is interconnected with the cardiovascular RAAS pharmacology that ACE inhibitors, ARBs and aldosterone antagonists target.
• Anyone with confirmed cerebral amyloid angiopathy (CAA), characterised by lobar microbleeds on susceptibility-weighted MRI — the angiogenic biology of HGF/c-Met has uncharacterised interaction with the abnormal vasculature of CAA.
• Anyone with a personal or strong family history of breast, ovarian, lung, gastric, colorectal or pancreatic cancer (c-Met-implicated tissues).
• Anyone enrolled in a vascular dementia clinical trial — concurrent unlicensed investigational agents would invalidate trial data and likely terminate participation. The MarkVCID consortium, NAC trials, CY6463 trials and emerging psoriasis-drug-repurposing trials all have prohibitions on concurrent investigational agents.
• Anyone with significant capacity concerns — informed consent is fundamental and capacity may be partially impaired in moderate-to-severe vascular dementia. Decisions about unlicensed therapy should involve the appointed lasting power of attorney for health and welfare; the editorial position is that such decisions should not be taken without specialist input.
• Anyone whose vascular dementia diagnosis is uncertain or pre-formal — the diagnostic clarity of a clean baseline matters more than experimental neuroplasticity.

Dosing Considerations Specific to Vascular Dementia

The community dose range for Dihexa, drawn from the 2026 review of self-reported protocols, is typically 8-25 mg/day orally or sublingually for 8-16 weeks, often cycled. Several considerations argue for the lower end of this range in vascular dementia specifically:

• Polypharmacy is the rule, not the exception: antihypertensives, statins, antiplatelets or anticoagulants, oral antidiabetics, antidepressants and sometimes cholinesterase inhibitors (in suspected mixed dementia) are typical concurrent prescriptions. Each represents an uncharacterised interaction.
• The cardiovascular comorbidity load means small acute effects on blood pressure, heart rate or coagulation could matter more than in younger or healthier populations. Symptoms suggesting orthostatic hypotension, palpitations, new bruising or unusual bleeding warrant immediate cessation.
• The vivid-dream and sleep-architecture effects (see the sleep & memory consolidation review) may interact unpredictably with already-disrupted VaD sleep patterns and may complicate any concurrent sedative or hypnotic use.
• Caregiver oversight matters substantially — capacity-related compliance, dose adherence and side-effect reporting all require involved caregiver engagement, particularly in mid-to-late-stage vascular dementia.
• Any new focal neurological symptoms, worsening of executive function, gait deterioration, urinary incontinence escalation or behavioural change should trigger immediate cessation pending specialist input.

Monitoring

If self-experimentation proceeds despite the foregoing, minimum monitoring should include: baseline neuropsychological assessment (typically through the memory clinic) before and after each cycle; standardised symptom and behaviour diary kept by the caregiver; baseline blood panel before and after each cycle (FBC including platelets, U&Es, LFTs, lipids, HbA1c, B12, folate, ferritin, TFTs); blood pressure (sitting and standing); regular cardiac rhythm assessment; and prompt reporting to the responsible GP, neurology service, memory clinic and (where applicable) stroke service of any cardiovascular, neurological or cognitive change.

When to Stop Immediately

New focal neurological symptoms (FAST-positive stroke features), new transient ischaemic attack, severe headache (particularly in CADASIL where it may herald stroke), new seizures, palpitations or new arrhythmia, unusual bruising or bleeding, sudden vision changes, new motor weakness or speech disturbance, suspected fall with possible head injury, new severe behavioural or cognitive deterioration, suicidal ideation, or any confirmed cancer diagnosis (particularly breast, lung, gastric, colorectal or pancreatic) all warrant urgent medical attention and immediate cessation pending specialist input. For suspected acute stroke or TIA, the priority is calling 999 or 111 for FAST assessment and acute stroke care; vascular dementia patients have substantially elevated stroke risk and recurrence and the priority is always the acute event.

The Evidence-Based 2026 Plan for Vascular Dementia-Affected Families in the UK

If you take one section of this article seriously, take this one. For a UK family with a confirmed or suspected vascular dementia diagnosis in 2026, here is the order of operations with the strongest evidence base.

1. Establish a clear diagnosis. If vascular dementia, mixed dementia or VCI has not been formally diagnosed in a memory clinic or specialist cognitive neurology service, ask your GP for that referral. The NHS NG97 pathway exists for this reason. Diagnostic clarity (VaD vs mixed dementia vs pure Alzheimer's) materially changes treatment options (cholinesterase inhibitors and memantine are NICE-allowed in suspected mixed disease but not pure VaD) and prognosis.
2. Aggressive cardiovascular risk-factor optimisation. This is the single highest-yield set of interventions in vascular dementia, full stop. Blood pressure target under 130/80 in tolerant patients (SPRINT-MIND benchmark); LDL cholesterol target as per cardiovascular risk; HbA1c target individualised; anticoagulation for atrial fibrillation; antiplatelet therapy for symptomatic atherosclerosis; smoking cessation; weight management; physical activity; moderate alcohol; hearing aid and vision optimisation. The 14 Lancet Commission modifiable risk factors are the prevention frame.
3. Engage UK vascular-dementia support organisations early. Alzheimer's Society Dementia Connect line (0333 150 3456); Dementia UK Admiral Nurse helpline (0800 888 6678); Stroke Association (0303 3033 100); Alzheimer's Research UK for research-funded information.
4. Consider genetic counselling if young-onset or strong family history. CADASIL (NOTCH3), CARASIL (HTRA1), COL4A1/A2 and Fabry small-vessel disease are all causes of young-onset vascular dementia and warrant NHS clinical genetics referral where suspected. The UCL Rare Dementia Support service runs specialist groups for CADASIL.
5. Plan ahead while capacity permits. Lasting power of attorney (both for property/finance and health/welfare), advance care planning, will review, financial planning and family conversations should be done while the patient has full capacity. Vascular dementia can progress in step-wise fashion with abrupt cognitive worsening after each new stroke, making forward planning particularly important.
6. Build multidisciplinary care. Stroke rehabilitation where applicable, cognitive rehabilitation (memory aids, executive-function strategies, environmental adaptation), occupational therapy for ADL support, specialist dementia nursing for ongoing support, social work for benefits and care planning. These are evidence-grade interventions in a way that no pharmacological option currently is.
7. Pharmacological symptom management as needed. SSRIs (sertraline or citalopram are common first choices) for the depression that frequently complicates VaD; trazodone for sleep; antipsychotics only if absolutely necessary, low-dose and time-limited. In suspected mixed dementia, NICE NG97 allows a trial of cholinesterase inhibitors (donepezil, rivastigmine or galantamine) under specialist guidance.
8. Consider clinical-trial participation. The NIHR Be Part of Research portal and Alzheimer's Research UK's Join Dementia Research register list actively-recruiting UK trials. For VCI, the MarkVCID consortium frame and emerging psoriasis-drug-repurposing studies are the leading directions; for CADASIL specifically, the Cambridge CADASIL clinic provides specialist access. Supervised access with safety monitoring is preferable to unsupervised self-experimentation in every dimension.
9. Address modifiable risk where applicable. Even after diagnosis, addressing modifiable vascular risk factors slows progression of subcortical ischaemic VaD and reduces recurrent stroke risk. The 2024 Lancet Commission frame applies as much to secondary prevention as to primary.
10. Caregiver support and burnout prevention. Vascular dementia caregiving has its own challenges — the step-wise course, the focal neurological symptoms, the disinhibition and executive dysfunction. Carers UK and the local NHS carers assessment process should be engaged; Admiral Nurse support is available via Dementia UK.

The Bottom Line: A Strikingly Clean Mechanism, a Strong Prevention Story, and Zero Human Dihexa Data

The 2026 reading on Dihexa for vascular dementia is, mechanistically, the most coherent on this site — and evidentially, no different from anywhere else. The mechanistic case is multi-level and unusually broad: vascular dementia is driven by cerebrovascular insufficiency, blood-brain-barrier dysfunction, chronic vascular inflammation and downstream cortical synaptic loss; the HGF/c-Met system supports cerebral angiogenesis, BBB sealing, microglial repolarisation and synaptogenesis. Dihexa is a positive modulator of HGF/c-Met. The mechanism deserves a real experiment — arguably more than in any other indication on this site.

And yet: there is no controlled human trial of Dihexa in vascular dementia, vascular cognitive impairment, cerebral small vessel disease, subcortical ischaemic VaD, multi-infarct dementia, post-stroke dementia, mixed dementia, CADASIL or any related condition. The closest clinical-stage relative, fosgonimeton, was developed for Alzheimer's and Parkinson's-related dementia and never advanced into a dedicated vascular dementia trial. The dominant 2025-2026 vascular dementia stories are the UCLA inflammation/brain-repair work, the UNSW CHeBA Mendelian-randomization genetics, the Manchester Kir2.1/amlodipine paper and the WSO 2026 Fact Sheet — all of which strengthen the case for a more multi-mechanism approach to VaD but none of which validate any specific unlicensed peptide.

The honest 2026 reading: aggressive cardiovascular risk-factor optimisation first (highest-evidence intervention in vascular dementia, full stop), NHS specialist memory-clinic diagnosis and multidisciplinary care second, support-organisation engagement throughout, clinical-trial participation via MarkVCID-frame studies and emerging psoriasis-drug-repurposing trials where appropriate third, and unlicensed peptides essentially last — if at all. The biology of vascular dementia deserves serious experimental investigation. Self-experimentation with an unstudied research peptide in a population already managing significant cardiovascular comorbidity, polypharmacy and (often) progressive cognitive impairment is not what serious investigation looks like, and it is not the right next step for most readers of this page.

Frequently Asked Questions

Related Reading on Dihexa.co.uk

• Dihexa for Huntington’s Disease: AMT-130, WVE-003, Votoplam & the 2026 UK Review — the autosomal-dominant single-gene neurodegeneration companion piece, covering the uniQure AMT-130 ~75% slowing of disease progression at 36 months (UCL/UCLH & Cardiff ANTC), the March 2026 FDA Type-A meeting requiring a sham-controlled Phase 3, the Wave Life Sciences WVE-003 SELECT-HD allele-selective mutant huntingtin lowering, the PTC votoplam PIVOT-HD 24-month extension & Novartis INVEST-HD, the corticostriatal BDNF axis and the HGF/c-Met synaptogenic case.
• Dihexa for Lewy Body Dementia (DLB) & Parkinson’s Disease Dementia (PDD) — the third-most-common dementia, mixed AD-DLB-vascular pathology context, the CervoMed neflamapimod RewinD-LB extension, AAN 2026 basal-forebrain MRI data, FDA-aligned Phase 3 path, and the alpha-synuclein seed-amplification assay backbone.
• Dihexa for Stroke Recovery & PSCI — the direct stroke-to-vascular-dementia continuum; post-stroke cognitive impairment; the 2025 European Stroke Organisation aphasia guideline.
• Dihexa for MCI & Brain Aging — the synaptic-loss case shared across dementia subtypes; the 2024 Lancet Commission's 14 modifiable risk factors; the 2026 NICE lecanemab and donanemab rejections.
• Dihexa & Alzheimer's Research — the Wright laboratory origin story; mixed Alzheimer-vascular pathology and where it overlaps.
• Dihexa for Diabetic Brain Fog — type 2 diabetes as a major vascular dementia risk factor; SGLT2 and GLP-1 cognitive evidence; the EVOKE / EVOKE+ semaglutide failure.
• Dihexa for Frontotemporal Dementia (FTD) — the second-young-onset-dementia review on this site; the latozinemab INFRONT-3 failure as a sobering parallel.
• Dihexa for Parkinson's Disease — the closely related fosgonimeton SHAPE PDD signal; the broader synucleinopathy / vasculopathy overlap.
• Dihexa for Multiple Sclerosis (MS) — the HGF/c-Met remyelination biology and a related neuroinflammation review.
• Dihexa for ALS & MND — the VM202 / Engensis plasmid HGF gene therapy programme and HGF motor-neuron-protection biology.
• Dihexa for Chemo Brain (CICI) — another cognitive-recovery indication with overlapping neuroinflammation biology.
• Dihexa for Long COVID Brain Fog — the shared microvascular and neuroinflammatory substrate that connects post-viral and vascular cognitive impairment.
• Dihexa for TBI & Concussion — TBI is a 2024 Lancet Commission modifiable dementia risk factor; the synaptic-rebuilding rationale.
• Dihexa for Anxiety & Chronic Stress — chronic stress raises blood pressure and accelerates cerebrovascular ageing.
• Dihexa for Depression & Mood — vascular depression is closely linked to subcortical ischaemic VaD biology.
• Dihexa, Sleep & Memory Consolidation — sleep disturbance is common in VaD; the glymphatic clearance story.
• Dihexa for ADHD — executive function and the prefrontal cortex angle shared with subcortical ischaemic VaD.
• Dihexa for Menopause Brain Fog — the menopause-cardiovascular-cognitive axis.
• Dihexa for PTSD & Complex PTSD — the chronic-stress-vascular axis and trauma-related cardiovascular risk.
• Dihexa vs BDNF — the BDNF axis in chronic cerebral hypoperfusion; the central potency claim, examined.
• Fosgonimeton & Athira — the closest clinical-stage relative and why no vascular dementia trials were ever run.
• Dihexa Review 2026 — effects timeline, oral vs sublingual, cycling protocols.
• Dihexa Stacking Guide — why combining Dihexa with antihypertensives, statins, antiplatelets or anticoagulants needs prescriber oversight.
• Dihexa for Cognitive Enhancement — the broader cognition conversation.
• Mechanism of Action — HGF/c-Met, PI-3K/AKT, dendritic spines, angiogenesis and the BBB.
• Benefits Overview — the broader claimed-benefit landscape, evidence-rated.
• Dosage Guide — community dose ranges and considerations.
• Side Effects & Risks — the general safety picture, including vascular-dementia-relevant polypharmacy concerns.
• UK Legal Status — where Dihexa sits in UK law.
• Research & Studies — the human and animal evidence base reviewed.
• Dihexa vs Other Nootropics — how Dihexa compares with Semax, Selank, Noopept, BPC-157, cerebrolysin and citicoline.
• Glossary — technical terms used on this page.
• Full Site FAQ — the broader question set across the site.

External Authoritative Sources Cited

• UCLA Health. Researchers uncover key mechanism of brain repair in vascular dementia, revealing promising therapeutic target (April 2026).
• Medical Xpress. Study identifies new treatment targets for vascular dementia (UNSW Sydney CHeBA, April 2026).
• University of Manchester Faculty of Biology, Medicine and Health. Blood vessel breakthrough is major step towards dementia treatment (Kir2.1 / amlodipine).
• Inside Precision Medicine. Vascular dementia study unveils brain repair mechanism, therapy target.
• Vascular dementia: World Stroke Organization fact sheet 2026. International Journal of Stroke, indexed on PubMed.
• World Stroke Academy. WSO Vascular Dementia Factsheet 2026 and New Podcast Series.
• Vascular cognitive impairment and dementia: Prevention, treatments, mechanisms and management options for the future. Neuropsychopharmacology (2026).
• Clinical Trials of New Drugs for Vascular Cognitive Impairment and Vascular Dementia. International Journal of Molecular Sciences (2022).
• Selective vulnerability of cerebral vasculature to NOTCH3 variants in small vessel disease and rescue by phosphodiesterase-5 inhibitor. Science Advances (2025).
• Disease Severity Staging System for NOTCH3-Associated Small Vessel Disease, Including CADASIL. JAMA Neurology (2024).
• Association of NOTCH3 Variant Risk Category With 2-Year Clinical and Radiologic Small Vessel Disease Progression in Patients With CADASIL. Neurology (2024).
• Livingston G et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission.
• Alzheimer's Disease International. Lancet Commission identifies two new risk factors for dementia and suggests 45% of cases could be delayed or reduced.
• Therapeutic potential of hepatocyte growth factor against cerebral ischemia (Review). Experimental and Therapeutic Medicine (via PMC).
• Strong neurogenesis, angiogenesis, synaptogenesis, and antifibrosis of hepatocyte growth factor in rats brain after transient middle cerebral artery occlusion. PubMed.
• Wright JW & Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Neuroscience (2015).
• Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the HGF/c-Met system.
• NICE NG97 — Dementia: assessment, management and support for people living with dementia and their carers.
• Alzheimer's Society. What is vascular dementia?
• Alzheimer's Research UK. Vascular dementia explained.
• NHS. Vascular dementia.
• Dementia UK. Admiral Nurse Dementia Helpline.
• Stroke Association (UK).
• Alzheimer's Society. Treatment and support for vascular dementia.
• NIHR Be Part of Research portal.
• Join Dementia Research (NIHR).
• UK Dementia Research Institute.